Proactive investors

Overview

Founded in February 2008 by a team of entrepreneurs with former corporate experience in consumer healthcare, we have established a platform of core technologies and products by acquisition, in-house development and in-licensing.

We operate from the United Kingdom working with a range of partners in pharmaceutical technology, drug delivery science, regulatory and manufacturing to provide a full product development solution.

ONG's business strategy is focused in the following areas:

Science In-licensing and patent development.

We have relationships with a number of high calibre Universities across the world and in particular Oxford University. Our expertise is in taking leading edge pharmaceutic and drug delivery science and adapting it for specific pharmaceutical product development. This way we work closely with the science to develop and patent unique product applications and formats.

We have a patent granted in the UK for high fibre soft chews as a delivery system for supplements and medicines and expect the European application to be granted shortly. We have also published patent applications for our unique chewable tablet and liquid suspension systems. We are continually working on new patents for specific format and therapeutic areas.

Development & Licensing of CTM dossiers

We use our patented and licensed technologies to develop full CTM dossiers which we then offer to relevant pharmaceutical companies under license, royalty and supply agreements.

We focus this work on sectors with a strong consumer or patient need so we can bring the products to market quickly. Our first products to market will be;

- 200mg and 400mg Chewable ibuprofen tablets using our fully taste masked ibuprofen technology and possible improved gastric benefits.

- 400mg ibuprofen per 5ml suspension, the first dosage for an adult ibuprofen suspension, again totally taste masked and possible gastric benefits.

We are putting in place a full technical dossier for the manufacture and supply of these products using chosen manufacturing partners. The products will be available for supply through our manufacturing partner or potentially made available under license for manufacture elsewhere via a license variation.

We are also working on a pipeline of products further exploiting the advantages of our drug delivery platforms and our new scientific licenses.

Technology licensing

In addition to developing and marketing our own dossiers we work with branded pharmaceutical companies to develop innovative new products for generic and soon to be off patent API's to provide differentiated products to compete with price driven generics. Identifying patient and commercial needs we work closely with the pharma company under a technology and royalty license to put together the full CTM for the new product, including where necessary any clinical studies.

Our technology is made available alongside agreed development and sales milestone payments and offered to the pharma partner for exclusive marketing incorporating our patent protection thereby extending their own protection for the now (or soon to be) generic API.

We also offer our technology to contract manufacturers to bring their own supplement products to market.

We are proud to offer a unique service by bringing together leading edge university science with leading edge product development to meet patient and market needs.

Sales and Marketing of Food Supplement Products

We also supply our own branded soft chew supplement products under the Ellactiva® and Chewyz™ brand which we offer as an export opportunity for distributors across the world. In addition we can supply bulk product under a private label arrangement with partner brands. The products leverage proprietary formulation and manufacturing know-how and our patent for the soft chew delivery format. We operate an out-sourced supply chain via contract manufacturing partners in Europe and a contract packer in the United Kingdom.

Marcelo Bravo, Executive Chairman

Marcelo Bravo is a founder of Oxford NutraScience Limited and an entrepreneur with a background in chemistry and chemical engineering and international experience with blue-chip companies. Marcelo spent 16 years in R&D with The Procter & Gamble Company and subsequently spent 3 years in corporate development with Boots (now Boots Alliance Plc). After this he became an entrepreneur and most recently was CEO and Board director of Oxford Advanced Surfaces Group Plc, a company he led from inception as a spin-out from Oxford University which is now quoted on the AIM market. Marcelo has extensive experience in developing, launching and growing new products and businesses across a range of both geographic and product markets. Marcelo holds a B.A. in Chemistry from the College of Wooster, USA and a B.Sc. in Chemical Engineering from Case Western Reserve University, USA and an M.Sc in Management from the London Business School.

Nigel Theobald, Chief Executive Officer

Nigel Theobald has a background in marketing and product development in the OTC consumer healthcare market as well as considerable business development experience with blue chip companies. Nigel worked for Boots (now Boots Alliance Plc) for 13 years in a number of commercial and strategic roles including Category Manager for OTC Medicines and Head of Healthcare Brand Development. Nigel set up a consultancy to advise ingredient technology firm Alltracel to launch new products and establish commercial partnerships and worked closely with established health care brands prior to setting up Omscan Ltd, a consumer healthcare production distribution business in the UK, which he sold in 2008. Nigel holds a B.Sc in Economics from Southampton University.

Mike Bretherton, Finance Director

Michael Bretherton graduated in Economics from University of Leeds in 1978. He worked as an accountant and manager with PriceWaterhouse for seven years in both London and the Middle East. He subsequently worked for The Plessey Company Plc before being appointed finance director of the fully listed Bridgend Group Plc in 1988 where he was involved in the strategic evaluation and commercial implementation of a broad range of business initiatives over a twelve year period. More recently he has worked at the property and services company, Mapeley Limited as financial operations director and then at the entertainment software games developer, Lionhead Studios Limited, in 2002 where he helped to complete a Venture Capital syndicate funding and also a trade sale of the business to Microsoft in 2006. Michael is currently an executive director of ORA Capital Partners Limited and is also a director for a number of other AIM quoted companies.

James White, Non Executive Director

James White has extensive experience in operations, product development, regulatory, sales and marketing and general management. James worked for Osmetech Plc for 11 years in a number of senior positions including as Chief Executive for the period 2000 to 2009. Osmetech has operations in the UK and USA and is focused on providing molecular diagnostic technologies through a global sales distribution network. James has a track record of mergers and acquisitions, disposals and fundraising in the UK, USA and Europe and was previously a senior consultant in Arthur D Little's corporate finance practice where he specialised in advising on investments in small and medium sized companies.